• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

First-line therapy for recurrent metastatic head and neck squamous cell carcinoma: every rose has its thorn.

作者信息

Hasan Dena, Brenner J Chad, Swiecicki Paul L, Heft Neal Molly E

机构信息

Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, MI, USA.

Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.

出版信息

Transl Cancer Res. 2025 Jul 30;14(7):3887-3891. doi: 10.21037/tcr-2025-782. Epub 2025 Jul 25.

DOI:10.21037/tcr-2025-782
PMID:40792138
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12335684/
Abstract
摘要

相似文献

1
First-line therapy for recurrent metastatic head and neck squamous cell carcinoma: every rose has its thorn.复发性转移性头颈部鳞状细胞癌的一线治疗：每朵玫瑰都有刺。
Transl Cancer Res. 2025 Jul 30;14(7):3887-3891. doi: 10.21037/tcr-2025-782. Epub 2025 Jul 25.
2
Neoadjuvant chemoimmunotherapy for locally advanced squamous cell carcinoma of the head and neck: Systematic review and meta-analysis.头颈部局部晚期鳞状细胞癌的新辅助化疗免疫治疗：系统评价与荟萃分析
Pharmacol Res. 2025 Feb;212:107598. doi: 10.1016/j.phrs.2025.107598. Epub 2025 Jan 11.
3
The molecular characteristics of recurrent/metastatic HPV-positive head and neck squamous cell carcinoma: A systematic review of the literature.复发性/转移性 HPV 阳性头颈部鳞状细胞癌的分子特征：文献系统综述。
Clin Otolaryngol. 2024 Jul;49(4):384-403. doi: 10.1111/coa.14161. Epub 2024 Apr 24.
4
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.纳武利尤单抗联合伊匹单抗对比纳武利尤单抗单药治疗头颈部复发或转移性鳞状细胞癌的疗效和安全性：Ⅱ期 CheckMate 714 随机临床试验。
JAMA Oncol. 2023 Jun 1;9(6):779-789. doi: 10.1001/jamaoncol.2023.0147.
5
Pembrolizumab with Carboplatin and Paclitaxel Versus Alternative Systemic Treatments Recommended for the First-Line Treatment of Recurrent/Metastatic Head and Neck Cancer: An Indirect Treatment Comparison.帕博利珠单抗联合卡铂和紫杉醇与推荐用于复发/转移性头颈癌一线治疗的其他全身治疗方法的间接治疗比较
Adv Ther. 2025 Jun;42(6):2690-2707. doi: 10.1007/s12325-025-03144-4. Epub 2025 Apr 24.
6
Efficacy of first-line systemic treatment regimens for recurrent/metastatic head and neck squamous cell carcinoma: a network meta-analysis.复发性/转移性头颈部鳞状细胞癌一线全身治疗方案的疗效：一项网状Meta分析
Eur Arch Otorhinolaryngol. 2023 Mar;280(3):1391-1401. doi: 10.1007/s00405-022-07673-4. Epub 2022 Oct 1.
7
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.帕博利珠单抗治疗头颈部复发或转移性鳞状细胞癌的安全性和临床活性（KEYNOTE-012）：一项开放标签、多中心、1b 期试验。
Lancet Oncol. 2016 Jul;17(7):956-965. doi: 10.1016/S1470-2045(16)30066-3. Epub 2016 May 27.
8
Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.帕博利珠单抗联合卡铂和紫杉醇作为复发性/转移性头颈部鳞状细胞癌的一线治疗（KEYNOTE-B10）：一项单臂 IV 期试验。
J Clin Oncol. 2024 Sep 1;42(25):2989-2999. doi: 10.1200/JCO.23.02625. Epub 2024 Jul 22.
9
A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy.正电子发射断层扫描在头颈部鳞状细胞癌放疗或放化疗后随访中作用的系统评价和荟萃分析
Clin Otolaryngol. 2008 Jun;33(3):210-22. doi: 10.1111/j.1749-4486.2008.01688.x.
10
Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: a multicenter, real-world, retrospective cohort study from China (NCT06478355).一线化疗免疫治疗联合或不联合放疗对局部晚期或转移性食管鳞状细胞癌患者预后的影响：一项来自中国的多中心、真实世界、回顾性队列研究（NCT06478355）
Front Immunol. 2025 Jul 28;16:1633930. doi: 10.3389/fimmu.2025.1633930. eCollection 2025.

本文引用的文献

1
Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC).铂类/紫杉类/帕博利珠单抗对比铂类/5-FU/帕博利珠单抗在复发性/转移性头颈部鳞状细胞癌（r/m HNSCC）中的应用。
Oral Oncol. 2024 Nov;158:106997. doi: 10.1016/j.oraloncology.2024.106997. Epub 2024 Aug 17.
2
Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.帕博利珠单抗联合卡铂和紫杉醇作为复发性/转移性头颈部鳞状细胞癌的一线治疗（KEYNOTE-B10）：一项单臂 IV 期试验。
J Clin Oncol. 2024 Sep 1;42(25):2989-2999. doi: 10.1200/JCO.23.02625. Epub 2024 Jul 22.
3
Patterns of recurrence in HNSCC patients treated definitively with upfront surgery, chemoradiation.
头颈部鳞状细胞癌患者经手术联合放化疗治疗后的复发模式。
Eur Arch Otorhinolaryngol. 2024 May;281(5):2645-2653. doi: 10.1007/s00405-024-08556-6. Epub 2024 Mar 18.
4
Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌的流行病学、危险因素和预防。
Med Sci (Basel). 2023 Jun 13;11(2):42. doi: 10.3390/medsci11020042.
5
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.纳武利尤单抗联合伊匹木单抗对比 EXTREME 方案作为复发/转移性头颈部鳞癌一线治疗：CheckMate 651 的最终结果。
J Clin Oncol. 2023 Apr 20;41(12):2166-2180. doi: 10.1200/JCO.22.00332. Epub 2022 Dec 6.
6
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.帕博利珠单抗联合或不联合化疗治疗复发性或转移性头颈部鳞状细胞癌：III 期 KEYNOTE-048 研究的更新结果。
J Clin Oncol. 2023 Feb 1;41(4):790-802. doi: 10.1200/JCO.21.02508. Epub 2022 Oct 11.
7
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗用于鳞状非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.
8
Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques.采用现代放射技术治疗后，局部晚期头颈部鳞状细胞癌患者的治疗失败模式和复发后结局。
JAMA Oncol. 2017 Nov 1;3(11):1487-1494. doi: 10.1001/jamaoncol.2017.0973.